
Claim your FREE PRIZE today by entering the Zenrelia competition*
Tell us about how your patients have found Zenrelia
We're looking for veterinary case studies that showcase the impact of Zenrelia in practice. We'll need a short description of their symptoms and progress made, along with a before and after photo.

Success Stories
Looking for ideas for how to write your case study? View our success stories:
What is Zenrelia?
Zenrelia is a NEW JAK inhibitor containing ilunocitinib for dogs with allergic and atopic dermatitis1.
It treats:
Questions?
*Full reference list below. Competition terms and conditions apply.
ASIT, allergen specific immunotherapy; PVAS, pruritus visual analogue scale.
- Zenrelia Summary of Product Characteristics
- Gedon NKY, Mueller RS. Clin Transl Allergy. 2018 Oct; 8:41.
- Bond R et al. Vet Rec. 2007 Apr; 160:503–6.
- Forster S et al. Vet Dermatol. 2025 Jul 31. doi: 10.1111/vde.70009
- Olivry T, Mueller RS. BMC Vet Res. 2017 Feb;13(1):51.
- Mueller RS et al. BMC Vet Res. 2016 Jan; 12:9.
- Mason K et al. Vet Dermatol. 2023 May;34:115–24



